USD 73.9 billion
Cancer Monoclonal Antibodies Market Size, Share, Growth Analysis, By Type (Human, Chimeric), By Application (Blood Cancer, Breast Cancer), By End-user (Hospitals, Research Institutes), By Region - Industry Forecast 2025-2032
Report ID:
SQMIG35H2308 |
Region:
Global |
Published Date: November, 2024
Pages:
211
|Tables:
88
|Figures:
71
Cancer Monoclonal Antibodies Market Insights
Cancer Monoclonal Antibodies Market size was valued at USD 87.5 Billion in 2023 and is poised to grow from USD 103.6 Billion in 2024 to USD 400.1 Billion by 2032, growing at a CAGR of 18.40% during the forecast period (2025-2032).
Along with radiation, chemotherapy, and surgery, monoclonal antibody-based immunotherapy is a vital part of the treatment arc for cancer. Over the last 20 years, it has been observed that mAbs have been featured as one of the most effective classes of treatments for both solid tumors and hematologic malignancies. Increasing incidence of cancer, new medication approvals, strong pipelines, and these trends are the main attractions that drive the market expansion. Present and upcoming therapies using monoclonal antibodies may help several millions of people globally. In addition, mAbs have fewer side effects on a patient's body compared to chemotherapy. Furthermore, increasing the adoption of more affordable biosimilar monoclonal antibodies by physicians and oncologists would further facilitate the market during the forecast period. Admittedly, severe cancer screening declined due to limited access to health systems to fight against the epidemic. For example, in April 2020, an 87% decline in breast cancer screening compared to the average for the same month during the prior five years was shown. This forced many cancer patients to delay or extend their treatment, raising concerns over access to the cancer drugs in time, recurrence of the disease, and cancelation of the cancer therapies. Cancer is a class of chronic diseases that is marked by uncontrolled cell growth. The growing incidence of cancer is predicted to act as a driver for market growth and demand for monoclonal antibodies.
Market snapshot - 2025-2032
Global Market Size
Largest Segment
Hospitals
Fastest Growth
Blood Cancer
Growth Rate
18.40%
Global Cancer Monoclonal Antibodies Market ($ Bn)
Country Share for North America Region (%)
To get more reports on the above market click here to Buy The Report
Cancer Monoclonal Antibodies Market Segmental Analysis
Global Cancer Monoclonal Antibodies Market is segmented by Type, Application, End-user, end user and region. Based on Type, the market is segmented into Humanized, Human, Chimeric, and Murine. Based on Application, the market is segmented into Blood Cancer, Breast Cancer, Lung Cancer, Melanoma, Colorectal Cancer, Liver Cancer, and Others. Based on End-user, the market is segmented into Hospitals, Research Institutes, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.
Analysis By Application
The blood cancer segment contributed to a share of 23.94% in 2023. This considerable share indicates that there has been major growth in access to therapies for hematological problems in the last three years. The growth in demand has pushed pharmaceutical companies to innovate and develop treatments, including advanced monoclonal antibodies for the treatment of cancer. This includes the approval by the FDA of GSK's BLENREP in August 2020. This dedication of the industry to treating hard-to-treat blood malignancies came as BLENREP was approved for use in the treatment of patients with refractory or relapsed multiple myeloma. This trend is an illustration of the progress made in the curing of hematological cancers besides the sustained focus on improving patient outcomes.
However, lung cancer is expected to grow the fastest at a CAGR of 21.2% during the forecast period. The factors expected to drive the demand for the product include the increasing burden of lung cancer. NSCLC accounted for about 85% of the total lung cancer burden, with the registration of over 2 million new cases across the globe in 2020 alone. It is therefore the most common form of the disease. In addition, the growing prevalence of the disease is driving the key players in the industry to implement developing initiatives that are expected to create opportunities for growth in the near term. The FDA approved Merck's application of KEYTRUDA in June 2022 for adjuvant treatment into Stage IB-IIIA non-small cell lung cancer after surgical resection.
Analysis By End User
The market share of the hospitals segment was 40.14% in 2023. The reasons for the leading position of the hospitals include growing incidence of cancer, increasing hospitalization rate, or fueling demand for inpatient therapies. In addition, when able to provide access to advanced medication therapy, hospitals are more preferred by the patients. The highly skilled professionals in advanced therapies have contributed to the growth of the sector. All these factors make hospitals the go-to option for the care of cancer, and thus, the strong market share with significant emphasis on the important role they will play in making the choice of treatment options for the patients more specialized and efficient.
The research institutes segment is growing at the fastest pace and presents comprehensive development opportunities. For instance, IRBM and The University of Texas MD Anderson Cancer Center manufactures therapeutic monoclonal antibodies targeting new immune checkpoint inhibitors through a collaboration deal signed in 2019. The deal illustrates the importance of doing novel cancer research. Equally, Celltrion Healthcare entered a strategic partnership with the Brazilian Ministry of Health in 2021 to bring to market two of its oncology treatments, Truxima and Herzuma. These strategic collaborations reflect the rapid developments going on in cancer therapy and symbolize increased investment in R&D.
Global Cancer Monoclonal Antibodies Market By Application
To get detailed analysis on other segments, Request For Free Sample Report
Cancer Monoclonal Antibodies Market Regional Insights
North America dominated the cancer monoclonal antibodies market with a dominant market share of 38.51% in 2023, and the region constituted the leading market due to strategic initiatives that had a big impact on market dynamics. One such instance can be viewed in the extensive global collaboration deal inked by AbbVie and I-Mab in September 2020. The collaboration agreement seeks the further development and commercialization of lemzoparlimab, a novel anti-CD47 monoclonal antibody for the treatment of multiple malignancies. This agreement opens possibilities for future cooperation in CD47-associated therapeutic molecules and at the same time reaffirms commitments toward the development of cancer therapeutics.
The highest growth, at a CAGR of 22.2%, is expected to be recorded in the Asia Pacific region because of various multinational companies that attempt to enter this market more aggressively than before to gain more significant shares of this new territory. Such an increase in market growth is expected to be witnessed due to the rise anticipated in national and international collaborations between agencies, most specifically for countries that are developed and in those which are considered emerging. In addition, rising biosimilars usage in the region will provide far greater avenues of revenue in the forecast period. For instance, the biosimilar drug market of China has gathered solid momentum in the last two years. In 2019, by the end of the year, there were 391 biosimilar drugs in study and development within the country-more than ever number of biosimilar drugs recorded. Up to the end of December 2020, eleven biosimilar medicines, of which six were cancer medications, had gained the right to enter the Chinese market.
Global Cancer Monoclonal Antibodies Market By Geography
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Cancer Monoclonal Antibodies Market Dynamics
Drivers
Increasing prevalence of Cancer
- The cancer monoclonal antibodies market has been highly influenced by the growing prevalence of cancer across the globe. Growing cases of cancer are necessitating the need for advanced and effective treatment solutions. Compared to traditional medicines, monoclonal antibodies are considered, especially for their precise targeting of cancerous cells, which frequently enhances the outcomes of patients and reduces side effects. Coupled with an ever-increasing demand for newer and innovative therapies, this demographic also creates a rationale for encouraging funds in R&D. Increased awareness of cancer, which enables early detection, furthers this booming market for these drugs and, in turn, encourages further development in cancer therapy.
Advancements in Biotechnology
- The market is essentially driven by improvements in biotechnology. Personalized medicine, advanced antibody engineering, and novel target identification methodologies have altogether contributed to a significant enhancement in the efficacy and specificity of monoclonal antibody therapy. These enabling technologies now allow the design of therapies tailored to the profile of each patient, thus improving therapeutic outcomes. Moreover, technological advances have made many of these drugs less expensive and more accessible because of enhancements in manufacturing and formulation processes. The continuous growth of the market for monoclonal antibodies is further driven by advances within biotechnological processes because such advancements not only expand their scope of use but also encourage further research and investment.
Restraints
High Costs of Treatment
- One major constraint is the high cost of monoclonal antibody therapy. Some of the reasons these therapies are very expensive include advanced manufacturing processes that they require and significant R&D. If these technologies are overly expensive, patient access will be limited, especially for low-income communities and countries whose healthcare systems are under budget. Such medicine one day might be unaffordable and burdensome to health care providers. Moreover, the high price will translate into an increase in out-of-pocket spending, consequently further restraining market growth and access.
Regulatory Challenges
- Regulatory challenges form part of the issues that might deter growth in the cancer monoclonal antibodies market. Approval for monoclonal antibodies is mostly protracted and involves extensive clinical trials to ensure that treatments are effective and safe. These can often be highly complex regulatory barriers that would be very costly and time-consuming to surmount, and thus may delay the launching of new therapies to the market. The process of product development and commercialization can be further exacerbated by different regulations in each location. Changes in regulatory policies and increased scrutiny can be a challenge to deal with and affect the overall market behavior and may delay the introduction of new therapeutic monoclonal antibodies.
Request Free Customization of this report to help us to meet your business objectives.
Cancer Monoclonal Antibodies Market Competitive Landscape
Most of the companies are promptly choosing partnership, mergers, and acquisitions in developing and economically viable regions other than strategic alliances. For instance, in March 2022, Sanofi and Seagen Inc. entered an exclusive agreement for the design, development, and commercialization of ADCs targeting up to three cancer targets.
Top Player’s Company Profiles
- AbbVie Inc. (US)
- Amgen Inc. (US)
- Merck & Co., Inc. (US)
- Bristol-Myers Squibb Company (US)
- Gilead Sciences, Inc. (US)
- Takeda Pharmaceutical Company (Japan)
- AstraZeneca plc (UK)
- Eli Lilly and Company (US)
- Regeneron Pharmaceuticals, Inc. (US)
- BeiGene, Ltd (China)
- Biogen Inc. (US)
- Recordati Industria Chimica e Farmaceutica S.p.A (Italy)
- Pfizer (US)
- Spectrum Pharmaceuticals, Inc. (US)
- Iovance Biotherapeutics, Inc. (US)
- Exelixis, Inc. (US)
- OncoOne (US)
- CureVac AG (Germany)
- Cellerant Therapeutics, Inc. (US)
- Celltrion, Inc. (South Korea)
- Faron Pharmaceuticals Ltd. (Finland)
Recent Developments
- In June 2022, the application from Merck for KEYTRUDA was approved by FDA as an adjuvant therapy for Stage IB-IIIA non-small cell lung cancer following surgical resection.
- In February 2022, the FDA approved CARVYKTI, ciltacabtagene autoleucel, cilta-cel, developed by Janssen Pharmaceutical Companies of Johnson & Johnson, for the treatment of adults with RRMM who have received four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody.
- In January 2022, CDE approved an Akeso Phase II clinical trial of the monoclonal antibody ligufalimab (AK117) and the bispecific antibody ivonescimab (AK112) for first-line breast cancer.
Cancer Monoclonal Antibodies Key Market Trends
- Emergence of Combination Therapy: One of the major trends in the cancer monoclonal antibodies market is the growing use of combination therapy. The administration of monoclonal antibodies together with other modes of treatment, such as immunotherapies, targeted treatments, or chemotherapy, has almost become a norm. It tries to attack multiple processes of cancer simultaneously, reduce resistance, and improve the efficacy of therapies. The combination of immune checkpoint inhibitors with monoclonal antibodies is such an instance, where deeper immune responses against tumor cells are mounted; this combination has brought promising improvement in patient outcomes. This trend therefore stipulates that the complexity of cancer is being put into light, and more diversified approaches toward treatments, hence more personalized and powerful options in treatments.
- Introduction of Biosimilars: Another major trend in the cancer monoclonal antibodies market is the rise of biosimilars. Biosimilars are inexpensive copies of original monoclonal antibody drugs with similar safety and efficiency profiles. The emergence of biosimilars into the market provides patients with more reasonable and affordable treatment options when the patents of widely used monoclonal antibodies expire. This trend promotes competition that will further drive innovation and development of antibody therapeutics beyond reducing healthcare costs.
Cancer Monoclonal Antibodies Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the increasing prevalence of cancer, coupled with increasing funding for genomic R&D, and the increasing need and advancements in the specificity of monoclonal antibodies targeting cancer, are some of the factors contributing to the market's growth. Moreover, there is a link between social and economic development and the increasing cancer burden caused by several factors, such as aging and growth of the population, and changes in the predominance of causes of cancer. The advanced new medical research breakthroughs, coupled with increased demand for innovative ways to treat cancer, is highlighted by these interrelated factors.
| Report Metric | Details |
|---|---|
| Market size value in 2023 | USD 87.5 Billion |
| Market size value in 2032 | USD 400.1 Billion |
| Growth Rate | 18.40% |
| Base year | 2024 |
| Forecast period | 2025-2032 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Cancer Monoclonal Antibodies Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Cancer Monoclonal Antibodies Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Cancer Monoclonal Antibodies Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Cancer Monoclonal Antibodies Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Cancer Monoclonal Antibodies Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Cancer Monoclonal Antibodies Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
